Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00692770 · ClinicalTrials.gov registry record · Phase 3
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
A Phase 3 study of Carcinoma, Hepatocellular, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,114
- Enrollment target
- 20
- Study locations
NCT00692770 is a Phase 3 study of Carcinoma, Hepatocellular that has completed, run by Bayer. The registered enrollment target is 1,114 participants, above the 571-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (95% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT00692770, a Phase 3 study of Carcinoma, Hepatocellular, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,114 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate efficacy and safety of sorafenib versus placebo in the adjuvant treatment of Hepatocellular Carcinoma (HCC) after potentially curative treatment (surgical resection or local ablation).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nexavar (Sorafenib, BAY43-9006)
Study Locations (20)
California
- - Los Angeles
- - Los Angeles
- - San Francisco
Massachusetts
- - Boston
- - Boston
- - Burlington
Minnesota
- - Minneapolis
- - Minneapolis
Alabama
- - Birmingham
Arizona
- - Phoenix
District of Columbia
- - Washington D.C.
Florida
- - Miami
Georgia
- - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,114 participants |
| Start Date | 2008-08-15 |
| Est. Completion | 2014-11-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00692770
The ClinicalTrials.gov registry entry for NCT00692770 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,114 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 571-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (95% higher). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Hepatocellular appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00692770 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Massachusetts, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00692770 about?
NCT00692770 is a clinical study titled "Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)". To evaluate efficacy and safety of sorafenib versus placebo in the adjuvant treatment of Hepatocellular Carcinoma (HCC) after potentially curative treatment (surgical resection or local ablation).
What is the current status of trial NCT00692770?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,114 participants. The study started on 2008-08-15. Estimated completion is 2014-11-28.
What conditions does trial NCT00692770 study?
This clinical trial studies the following conditions: Carcinoma, Hepatocellular.
What interventions are being tested in trial NCT00692770?
The interventions under investigation include: Placebo (DRUG), Nexavar (Sorafenib, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00692770?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00692770 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Hepatocellular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
COMPLETED · Phase 3
-
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
COMPLETED · Phase 3
-
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
COMPLETED · Phase 3
-
90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.